Breast Cancer, Soft-tissue Sarcoma, Solid Tumors
Conditions
Keywords
Advanced Soft-tissue Sarcoma, Advanced Breast Cancer, Maximum Tolerated Dose, Efficacy and safety, Immunotherapy
Brief summary
Assessment of the efficacy and safety of JX-594 and metronomic cyclophosphamide in patients with advanced soft-tissue sarcoma and advanced breast cancer, once the Maximum Tolerated Dose have been determined (phase I trial). Phase I study: this is a prospective open-labeled phase I trial based on a dose escalating study design assessing two dose levels of JX594 when prescribed in combination with metronomic cyclophosphamide. Phase II trials with two treatments strategies: Metronomic CP + JX-594: phase II study sarcoma: this is a monocentric, randomized two-arm non comparative phase 2 study assessing efficacy and safety of JX-594 in association with metronomic cyclophosphamide in patients with advanced soft-tissue sarcoma. Metronomic CP + JX-594: phase II study breast cancer: this is a monocentric, single-arm phase II study, assessing efficacy and safety of JX-594 in association with metronomic cyclophosphamide in patients with advanced breast cancer. Metronomic CP + JX-594 + Avelumab: phase II study sarcoma: this is a monocentric, single arm phase II study assessing efficacy and safety of avelumab in combination with IT JX-594 and metronomic cyclophosphamide in patients with advanced soft-tissue sarcoma. Metronomic CP + JX-594 + Avelumab:: phase II study breast cancer: this is a monocentric, single-arm phase II study, assessing efficacy and safety of avelumab in combination with IT JX-594 and metronomic cyclophosphamide in patients with advanced breast cancer.
Detailed description
For the phase I study, this is a prospective open-label phase I trial based on a dose escalating study design assessing two dose level of JX-594 when associated to metronomic cyclophosphamide. For the phase II study, two distincts treatment strategies will be evaluated. First, treatment by JX-594 and metronomic cyclophosphamide: * stratum soft-tissue sarcoma, this is a monocenter, randomized non comparative phase II clinical trial. This phase II trial was based on an optimal 2-stage Simon's design. Randomization 2:1 with 2 patients randomized in experimental arm n°1 (association of metronomic cyclophosphamide and JX-594) and 1 patient randomized in control arm n°2 (treatment by metronomic cyclophosphamide alone). * stratum breast cancer, this is a monocenter, one-arm phase II clinical trial, based on two-stage optimal Simon's design (association of metronomic cyclophosphamide and JX-594). Second, treatment by Avelumab, intratumoral JX-594 and metronomic cyclophosphamide: * stratum soft-tissue sarcoma, this is a monocenter, single arm phase II clinical trial based on an optimal 2-stage Simon's design. * stratum breast cancer, this is a monocenter, one-arm phase II clinical trial, based on two-stage optimal Simon's design).
Interventions
DRUGCyclophosphamide and JX-594 dose escalation
Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
DRUGCyclophosphamide and JX-594
Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
DRUGCyclophosphamide
Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off.
DRUGAvelumab and JX-594 and Cyclophosphamide
Avelumab will be administered by intravenous infusion (10 mg/kg) every 2 weeks, starting at Day 15 of cycle 1. Cyclophosphamide wil be administered bi-daily (50 mg x 2), starting 7 days prior to cycle 1 day 1 (impregnation phase) and given on a week on/week off schedule. JX-594 will be administered by intratumoral injection (1 x109 p.f.u) on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections .
Sponsors
National Cancer Institute, France
Fondation ARC
Merck Sharp & Dohme LLC
Transgene
Institut Bergonié
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Main Inclusion Criteria: 1. Histology: * Phase Ib : Patient with histologically confirmed solid tumor * Phase II : * Patients with histologically confirmed HER2 negative breast cancer (treatment by CP+JX-594), or triple negative (treatment by avelumab + CP+JX-594) * Patients with histologically confirmed soft tissue sarcoma confirmed by the RRePS Network, b)Progressive disease or relapse, after standard therapy according to RECIST v1.1 criteria diagnosed on the basis of two CT scan or MRI obtained at an interval less than 6 months in the period of 12 months prior to inclusion and confirmed by central review 2. Metastatic or unresectable locally advanced disease 3. Age ≥ 18 years 4. ECOG ≤ 1 (Phase Ib), ≤ 2 (Phase II JX+CP) and ≤ 1 (Phase II avelumab+JX+CP). 5. Life expectancy \> 3 months, 6. Measurable disease according to RECIST v1.1 outside any previously irradiated field. For patients treated by avelumab+JX+CP, at least one injectable site ≥ 2 cm and ≤ 8 cm in diameter and one distant non-injected measurable site (target site) 7. At least three weeks since last chemotherapy, immunotherapy or any other pharmacological treatment and/or radiotherapy. 8. Adequate hematological, renal, metabolic and hepatic functions. 9. Women of childbearing potential must have a negative serum pregnancy test before study entry. Both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for six months after discontinuation of treatment. 10. Patients informed of risks regarding drug interactions: patients receiving any substances that are inhibitors or inducers of CYP450 2B6 are ineligible 11. Voluntarily signed and dated written informed consent prior to any study specific procedure. 12. Patients with a social security in compliance with the French law. Main
Exclusion criteria
1. Previous treatment with JX-594 or other vaccina vector based treatment . 2. Concomitant diseases/conditions (non exhaustive list): 1. Clinically significant immunodeficiency, such as HIV or active Hepatite B or C 2. Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patient's participation in this study. 3. History of severe exfoliative skins condition requiring systemic treatment for more than 4 weeks in the last two years. 4. active autoimmune disease for patients treated by avelumab 3. Active central nervous system metastasis (CNS) 4. Participation to a study involving a medical or therapeutic intervention in the last 30 days. 5. Previous enrolment in the present study. 6. Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons. 7. Known hypersensitivity to any involved study drug or any of its formulation components. 8. Use of steroids (any route of administration), interferon/pegylated interferon or ribavirin that cannot be discontinued within 14 days prior to any JX-594 dose. 9. No prior malignancy except for the following: adequately treated basal or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage 1 or Stage 2 cancer from which the patient is currently in complete remission or any other cancer from which the patient has been disease-free for 3 years. 10. Active cardiovascular disease, including but not limited to significant coronary artery disease (e.g. requiring angioplasty or stenting) or congestive heart failure within the preceding 12 months. (treatment by CP+JX) 11. Inability to suspend treatment with anti-hypertensive medication for 48 hours prior to and 48 hours after all JX-594 treatments. 12. Pulse oximetry O2 saturation \< 90% at rest on room air. 13. Experienced a severe systemic reaction or side-effect as result of previous smallpox vaccination. 14. Cardiac disease: LVEF out of normal limits ; cumulative dose of anthracyclines in excess of 450 mg/m² 15. Known urinary tract obstruction 16. Household contact exclusions for patients enrolled: children\< 1 year old ; People with skin disease (e.g., eczema, atopic dermatitis and related diseases…), Immunocompromised hosts (severe deficiencies in cell-mediated immunity, including AIDS, organ transplant recipients, hematologic malignancies) 17. Vaccination within 4 weeks of the first dose of study treatment and while on trial is prohibited except for administration of inactivated vaccines.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase Ib : Maximum Tolerated Dose evaluated on the first cycle (D1 to D28) of the combination of JX-594 And metronomic cyclophosphamide | during the first cycle (28 days) | the MTD is defined as the highest dose at which no more than 1 in 6 of the patients in the cohort experienced a DLT in the first treatment cycle |
| Phase II : Advanced soft-tissue sarcoma: Assessment of the antitumor activity of the association of JX-594 and metronomic cyclophosphamide based on 6 month non-progression (CR, PR or SD more than 24 weeks) following RECIST v1.1 criteria | Phase II : 6 months after the beginning of treatment | Non-progression is defined as complete or partial response or stable disease, as per RECIST v1.1 |
| Phase II : Advanced Breast cancer: Assessment of the antitumor activity of the association of JX-594 and metronomic cyclophosphamide Efficacy will be defined based on objective response under treatment (CR or PR) following RECIST v1.1 criteria | Phase II : 6 months after the beginning of treatment | Objective response is defined as complete or partial response as per RECIST v1.1 |
| Phase II : Advanced soft-tissue sarcoma: Assessment of the antitumor activity of Avelumab in combination with IT JX-594 and metronomic cyclophosphamide based on 6 month non-progression (CR, PR or SD more than 24 weeks) following RECIST v1.1 criteria | Phase II : 6 months after the beginning of treatment | Non-progression is defined as complete or partial response or stable disease, as per RECIST v1.1 |
| Phase II : Advanced Breast cancer: Assessment of the antitumor activity of avelumab in combination with IT JX-594 and metronomic cyclophosphamide Efficacy will be defined based on objective response under treatment following RECIST v1.1 criteria | Phase II : 6 months after the beginning of treatment | Objective response is defined as complete or partial response as per RECIST v1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Phase Ib: 2-year progression-free survival as per RECIST V1.1 | 2-year after the beginning of treatment | PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause) |
| Phase Ib : Pharmacokinetics (PK): PK measurements expressed as Area Under the curve forJX-594 | Day 8 of cycle 1, Day 15 of cycle 1, Day 22 of cycle 1, Day 1 of cycle 2, Day 8 of cycle 2, Day 22 of cycle 2, Day 8 of cycle 3, Day 8 of cycle 4, Day 8 of cycle 6 (Each cycle = 28 days) | — |
| Phase Ib : Pharmacokinetics (PK): PK measurements expressed as half-life forJX-594 | Day 8 of cycle 1, Day 15 of cycle 1, Day 22 of cycle 1, Day 1 of cycle 2, Day 8 of cycle 2, Day 22 of cycle 2, Day 8 of cycle 3, Day 8 of cycle 4, Day 8 of cycle 6 (Each cycle = 28 days) | — |
| Phase Ib : Pharmacokinetics (PK): PK measurements expressed as Concentration peak forJX-594 | Day 8 of cycle 1, Day 15 of cycle 1, Day 22 of cycle 1, Day 1 of cycle 2, Day 8 of cycle 2, Day 22 of cycle 2, Day 8 of cycle 3, Day 8 of cycle 4, Day 8 of cycle 6 (Each cycle = 28 days) | — |
| Phase Ib : Dose-Limiting toxicity of the association of JX-594 and metronomic cyclophosphamide | during the first cycle (cycle = 28 days) | — |
| Phase Ib : Predictive biomarkers analysis (cytokines levels) | baseline, day 8 of cycle 1, day 22 of cycle 1, day 8 of cycle 2, day 8 of cycle 4, day 8 of cycle 6. Each cycle = 28 days | — |
| Phase Ib : Predictive biomarkers analysis (lymphocytes levels) | baseline, day 8 of cycle 1, day 22 of cycle 1, day 8 of cycle 2, day 8 of cycle 4, day 8 of cycle 6. Each cycle = 28 days | — |
| Phase II : Best overall response defined as per RECIST v1.1 criteria | an average of 6 months | Best overall response is defined as the best response recorded from the start of the study treatment until the end of treatment taking into account any requirement for confirmation (as per RECIST v1.1). |
| Phase II : For sarcoma only: objective response following CHOI criteria | an average of 6 months | — |
| Phase II : For sarcoma only: best overall response following CHOI criteria | an average of 6 months | — |
| Phase II : For sarcoma only: 6- month non-progression following CHOI criteria | 6-months after the beginning of treatment | — |
| Phase II : 1-year Progression-Free Survival (PFS) defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause), whichever occurs first | one year after the beginning of treatment | PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause) |
| Phase II : 2-year Progression-Free Survival (PFS) defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause), whichever occurs first | two years the beginning of treatment | PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause) |
| Phase II : 1-year Overall Survial (OS) defined as the time from study treatment initiation to death (of any cause) | one year after the beginning of treatment | OS defined as the time from study treatment initiation to death (of any cause) |
| Phase II : 2-year Overall Survial (OS) defined as the time from study treatment initiation to death (of any cause) | two year after the beginning of treatment | OS defined as the time from study treatment initiation to death (of any cause) |
| Phase II : Toxicity graded using the common toxicity criteria from the NCI v4.0 | an average of 6 months | assessef with NCI-CTCAE V4 |
| Predictive biomarkers (cytokines level) | baseline, day 8 of cycle 1, day 22 of cycle 1, day 8 of cycle 2, day 8 of cycle 4, day 8 of cycle 6. Each cycle = 28 days | — |
| Predictive biomarkers (lymphocytes level) | baseline, day 8 of cycle 1, day 22 of cycle 1, day 8 of cycle 2, day 8 of cycle 4, day 8 of cycle 6. Each cycle = 28 days | — |
| Phase II : Relationship between levels of anti-JX-594 antibodies and efficacy of CP + JX-594 in terms of 6-month non progression for sarcoma (as per RECIST V1.1) | Six months after the beginning of treatment | — |
| Phase II : Relationship between levels of anti-JX-594 antibodies and efficacy of CP + JX-594 in terms of objective response for breast cancer (as per RECIST V1.1) | an average of 6 months | — |
| Phase II : Relationship between activation of the pRB/E2F/TK pathway and efficacy of CP + JX-594 on available archived tumor tissue in terms of 6- month non progression for sarcoma (as per RECIST V1.1) | Phase II : Six months after the beginning of treatment | — |
| Phase II : Relationship between activation of the pRB/E2F/TK pathway and efficacy of CP + JX-594 on available archived tumor tissue in terms objective response for breast cancer (as per RECIST V1.1) | an average of 6 months | — |
| Phase II Soft-tissue sarcoma: antitumor actiivty of avelumab in combination with IT JX-594 and metronomic CP in terms of best overall response | an average of 6 months | \- Best overall response is defined as the best response recorded from the start of the study treatment until the end of treatment taking into account any requirement for confirmation (as per RECIST v1.1) |
| Phase II Breast cancer: antitumor actiivty of avelumab in combination with IT JX-594 and metronomic CP in terms of best overall response | an average of 6 months | \- Best overall response is defined as the best response recorded from the start of the study treatment until the end of treatment taking into account any requirement for confirmation (as per RECIST v1.1) |
| Phase II Breast cancer: antitumor actiivty of avelumab in combination with IT JX-594 and metronomic CP in terms of 6-month non-progression | 6 months | Non-progression is defined as complete or partial response or stable disease, as per RECIST v1.1 |
| Phase II Soft-tissue sarcoma: antitumor actiivty of avelumab in combination with IT JX-594 and metronomic CP in terms of objective response Under treatment | an average of 6 months | Objective response is defined as complete or partial response as per RECIST v1.1 |
| Phase II Soft-tissue sarcoma: antitumor actiivty of avelumab in combination with IT JX-594 and metronomic CP in terms of 1-year progression-free survival | 1 year | PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause) |
| Phase II Breast cancer: antitumor actiivty of avelumab in combination with IT JX-594 and metronomic CP in terms of 1-year progression-free survival | 1 year | PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause) |
| Phase II Soft-tissue sarcoma: antitumor actiivty of avelumab in combination with IT JX-594 and metronomic CP in terms of 2-year progression-free survival | 2 years | PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause) |
| Phase II Breast cancer: antitumor activity of avelumab in combination with IT JX-594 and metronomic CP in terms of 2-year progression-free survival | 2 years | PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause) |
| Phase II Soft-tissue sarcoma: antitumor activity of avelumab in combination with IT JX-594 and metronomic CP in terms of 1-year overall survival | 1 year | OS defined as the time from study treatment initiation to death (of any cause) |
| Phase II Breast cancer: antitumor activity of avelumab in combination with IT JX-594 and metronomic CP in terms of 1-year overall survival | 1 year | OS defined as the time from study treatment initiation to death (of any cause) |
| Phase II Soft-tissue sarcoma: antitumor activity of avelumab in combination with IT JX-594 and metronomic CP in terms of 2-year overall survival | 2 year | OS defined as the time from study treatment initiation to death (of any cause) |
| Phase II Breast cancer: antitumor activity of avelumab in combination with IT JX-594 and metronomic CP in terms of 2-year overall survival | 2 year | OS defined as the time from study treatment initiation to death (of any cause) |
| Phase II Soft-tissue sarcoma: safety profile of avelumab in combination with IT JX-594 and metronomic CP | throughout the treatment period, an expected average of 6 months | Safety profile will be assessed as per NCI-CTCAE v5 |
| Phase Ib : Recommended Phase II dose (RP2D) of the association of JX-594 and metronomic cyclophosphamide | Phase Ib : Throughout the 6 months of treatment period | Data from all cycles will be used to define the dose level of JX-594 to be recommended for further investigations in phase II |
| Phase II breast cancer: safety profile of avelumab in combination with IT JX-594 and metronomic CP | throughout the treatment period, an expected average of 6 months | Safety profile will be assessed as per NCI-CTCAE v5 |
| Phase Ib: Objective response under treatment as per RECIST V1.1 | an average of 6 months | Objective response is defined as complete or partial response as per RECIST v1.1 |
| Phase Ib: Best overall response as per RECIST V1.1 | an average of 6 months | \- Best overall response is defined as the best response recorded from the start of the study treatment until the end of treatment taking into account any requirement for confirmation (as per RECIST v1.1). |
| Phase Ib: 6-months non-progression as per RECIST V1.1 | 6-months after the beginning of treatment | Non-progression is defined as complete or partial response or stable disease, as per RECIST v1.1 |
| Phase Ib: 1-year progression-free survival as per RECIST V1.1 | 1-year after the beginning of treatment | PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause) |
Countries
France
Contacts
Primary ContactAntoine ITALIANO, MD, PhD
Outcome results
None listed